|
ACCREDITATION AND CREDITS
EXCEL Continuing Education is accredited by the
Accreditation Council for Continuing Medical education
(ACCME) to sponsor continuing medical education
for physicians.
EXCEL Continuing Education designates this educational
activity for a maximum of 3.5 AMA PRA
Category 1 Credit™. Physicians should only claim
credit commensurate with the extent of their participation
in the activity.
EXCEL Continuing Education is accredited by the
FL Board of Nursing Provider # 50-619 and designates
this activity for 3.5 contact hours.
EDUCATIONAL OBJECTIVES
Upon completion of this activity, the participants
should be able to:
• Explain the basis for risk of stroke in patients with
atrial fibrillation (AF).
• Discuss the efficacy of antiarrhythmic and antithrombotic
therapy to reduce this risk.
• Implement guideline and evidence-based
approaches for stroke prevention in AF for patients
in whom anticoagulant therapy is indicated and for
those in whom it is contraindicated.
• Describe the impact of suboptimal antithrombotic
prescribing practices and that of patients’ low adherence
to medications and initiate strategies to improve
clinical outcomes.
• Summarize the role of platelet in thrombosis and
latest data regarding antiplatelet therapy for AF
related stroke prevention.
TARGET AUDIENCE / PROGRAM OVERVIEW / NEEDS ASSESSEMENT
This activity has been designed to meet the educational
needs of practicing clinicians, and is targeted
to cardiologists, electrophysiologists, internists, PCs
and allied HCPs who treat patients for CV disease
and who must maintain a current understanding of
cardiac arrhythmias, its various manifestations, and
available and emerging treatment options for stroke
prevention in patients with AF.
The goal of this conference is two-fold: first, to highlight
the under-recognized risk of stroke and/or inadequate
prophylaxis in patients with AF and the
associated morbidity, mortality, and cost burdens;
and second, to educate CV physicians and allied
HCPs by providing a comprehensive review of the
most current evidence-based therapeutic strategies
for the prevention of stroke in patients with AF.
SUPPORTER
|
